ArticleBMC neuroscience2026
Pretreatment with the psychedelic DOI mitigates LPS-induced hippocampal inflammation and behavioral impairments in mice.
Article in BMC neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundNeuroinflammation is a hallmark of numerous neuropsychiatric and neurodegenerative disorders. Psychedelics have garnered recent attention for their anti-inflammatory and neuroprotective effects. However, it remains unknown whether they can prophylactically prime immune pathways to prevent subsequent neuroinflammatory responses, and whether such effects depend on serotonin 5-HT2A receptor (5-HT2AR) signaling.
methodsTo characterize the inflammatory time-course, wild-type (WT) male mice received LPS (1 mg/kg, i.p.) and hippocampi were collected 2, 4, 6, 8, or 24 h later. In a separate WT cohort, basal cytokine effects of the psychedelic (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) were examined following administration of varying doses or vehicle, with tissue collected 24 h later. For prophylactic studies, WT and 5-HT2AR-KO mice were pretreated with DOI (0.3 or 1 mg/kg) or saline 24 h before LPS challenge. Behavioral assays included locomotor activity, the forced swim test (FST), and body weight monitoring. Hippocampal cytokines (IL-6, TNF-α, IFN-γ, IL-5, IL-4, IL-10, IL-13, IL-2) were quantified with a multiplex bead-based assay, and correlations between cytokine levels and FST immobility were assessed.
resultsLPS induced robust hippocampal increases in IL-6 and TNF-α and produced sickness-related behavioral deficits. DOI pretreatment (0.3 mg/kg, and to a lesser extent 1 m/kg) attenuated LPS-evoked IL-6 and TNF-α elevations, restored locomotor activity, reduced FST immobility, and accelerated recovery of body weight. These anti-inflammatory effects were partially preserved in 5-HT2AR-KO mice, indicating both receptor-dependent and receptor-independent mechanisms. Notably, 5-HT2AR-KO mice displayed exaggerated cytokine responses to LPS relative to WT animals. Correlation analyses revealed a positive association between hippocampal IL-6 levels and depressive-like behavior, whereas IL-13 and IL-2 levels were inversely correlated with immobility time in the FST.
conclusionsProphylactic DOI administration establishes a sustained neuroimmune state that mitigates subsequent hippocampal inflammation and behavioral impairments, through mechanisms that are partially dependent on 5-HT2ARs. These findings suggest that serotonergic psychedelics can prime neural-immune interactions to confer long-lasting resilience against neuroinflammatory insults, offering a potential framework for developing next-generation psychedelic therapeutics with prophylactic anti-inflammatory and neuroprotective efficacy in neuropsychiatric and neurodegenerative disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.